Sequential FDG-PET and induction chemotherapy in locally advanced adenocarcinoma of the Oesophago-gastric junction (AEG): The Heidelberg Imaging program in Cancer of the oesophago-gastric junction during Neoadjuvant treatment: HICON trial

BMC Cancer

Volumn 11, Issue , 2011, Pages

  Lorenzen, Sylvie ^a   von Gall, Carl ^a   Stange, Annika ^a   Haag, Georg M ^a   Weitz, Jürgen ^b   Haberkorn, Uwe ^a   Lordick, Florian ^c   Weichert, Wilko ^a   Abel, Ulrich ^a   Debus, Jürgen ^a   Jäger, Dirk ^a   Münter, Marc W ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^c KLINIKUM BRAUNSCHWEIG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; CISPLATIN; DOCETAXEL; EPIRUBICIN; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; OXALIPLATIN; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DIAGNOSTIC AGENT; DRUG DERIVATIVE; FLUORINE; PLATINUM COMPLEX; RADIOPHARMACEUTICAL AGENT; TAXOID;

ADENOCARCINOMA OF THE ESOPHAGOGASTRIC JUNCTION; ARTICLE; CANCER ADJUVANT THERAPY; CHEMORADIOTHERAPY; CLINICAL TRIAL; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS RESECTION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; POSITRON EMISSION TOMOGRAPHY; PROSPECTIVE STUDY; RADIOACTIVITY; TREATMENT OUTCOME; TREATMENT RESPONSE; ADENOCARCINOMA; ADJUVANT THERAPY; CLINICAL TRIAL (TOPIC); ESOPHAGUS TUMOR; GERMANY; LOWER ESOPHAGUS SPHINCTER; METHODOLOGY; MULTICENTER STUDY (TOPIC); MULTIMODALITY CANCER THERAPY; PATHOLOGY; PATIENT SELECTION; SALVAGE THERAPY; SCINTISCANNING;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; CISPLATIN; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; EPIRUBICIN; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; ESOPHAGOGASTRIC JUNCTION; FLUORINE RADIOISOTOPES; FLUORODEOXYGLUCOSE F18; FLUOROURACIL; GERMANY; HUMANS; MULTICENTER STUDIES AS TOPIC; NEOADJUVANT THERAPY; ORGANOPLATINUM COMPOUNDS; PATIENT SELECTION; POSITRON-EMISSION TOMOGRAPHY; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; SALVAGE THERAPY; TAXOIDS; TREATMENT OUTCOME;

EID: 79959467695     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-266     Document Type: Article

References (23)

1. Parkin DM. International variation. Oncogene 2004, 23(38):6329-6340. 10.1038/sj.onc.1207726, 15322508.
2. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ. Cancer statistics, 2005. CA Cancer J Clin 2005, 55(1):10-30. 10.3322/canjclin.55.1.10, 15661684.
3. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006, 355(1):11-20. 10.1056/NEJMoa055531, 16822992.
4. Gebski V, Burmeister B, Smithers BM, Foo K, Zalcberg J, Simes J. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol 2007, 8(3):226-234. 10.1016/S1470-2045(07)70039-6, 17329193.
5. Kelsen DP, Ginsberg R, Pajak TF, Sheahan DG, Gunderson L, Mortimer J, Estes N, Haller DG, Ajani J, Kocha W, et al. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med 1998, 339(27):1979-1984. 10.1056/NEJM199812313392704, 9869669.
6. Ott K, Weber WA, Lordick F, Becker K, Busch R, Herrmann K, Wieder H, Fink U, Schwaiger M, Siewert JR. Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction. J Clin Oncol 2006, 24(29):4692-4698. 10.1200/JCO.2006.06.7801, 16966684.
7. Samalin E, Ychou M. Neoadjuvant treatment in upper gastrointestinal adenocarcinomas: new paradigms from old concepts?. Curr Opin Oncol 2007, 19(4):384-389. 10.1097/CCO.0b013e3281a73674, 17545805.
8. Lordick F, Ott K, Krause BJ, Weber WA, Becker K, Stein HJ, Lorenzen S, Schuster T, Wieder H, Herrmann K, et al. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. Lancet Oncol 2007, 8(9):797-805. 10.1016/S1470-2045(07)70244-9, 17693134.
9. Siewert JR, Lordick F, Ott K, Stein HJ, Weber WA, Becker K, Peschel C, Fink U, Schwaiger M. Induction chemotherapy in Barrett cancer: influence on surgical risk and outcome. Ann Surg 2007, 246(4):624-628. discussion 628-631, 10.1097/SLA.0b013e318155a7d1, 17893499.
10. Lordick F, Meyer Zum Bueschenfelde C, Herrmann K. PET-guided treatment in locally advanced adenocarcinoma of the esophagogastric junction (AEG): The MUNICON-II study. American Society of Clinical Oncology GI Cancer Symposium 2011 2011, San Francisco CA (J Clin Oncol 29: 2011 (suppl 4; abstr 3)).
11. Wieder HA, Beer AJ, Lordick F, Ott K, Fischer M, Rummeny EJ, Ziegler S, Siewer JR, Schwaiger M, Weber WA. Comparison of changes in tumor metabolic activity and tumor size during chemotherapy of adenocarcinomas of the esophagogastric junction. J Nucl Med 2005, 46(12):2029-2034.
12. Weber WA, Ott K, Becker K, Dittler HJ, Helmberger H, Avril NE, Meisetschlager G, Busch R, Siewert JR, Schwaiger M, et al. Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol 2001, 19(12):3058-3065.
13. Roth AD, Fazio N, Stupp R, Falk S, Bernhard J, Saletti P, Koberle D, Borner MM, Rufibach K, Maibach R, et al. Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research. J Clin Oncol 2007, 25(22):3217-3223. 10.1200/JCO.2006.08.0135, 17664469.
14. Lorenzen S, Hentrich M, Haberl C, Heinemann V, Schuster T, Seroneit T, Roethling N, Peschel C, Lordick F. Split-dose docetaxel, cisplatin and leucovorin/fluorouracil as first-line therapy in advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: results of a phase II trial. Ann Oncol 2007, 18(10):1673-1679. 10.1093/annonc/mdm269, 17660494.
15. Stahl M, Walz MK, Stuschke M, Lehmann N, Meyer HJ, Riera-Knorrenschild J, Langer P, Engenhart-Cabillic R, Bitzer M, Konigsrainer A, et al. Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol 2009, 27(6):851-856. 10.1200/JCO.2008.17.0506, 19139439.
16. Siewert JR, Stein HJ. Classification of adenocarcinoma of the oesophagogastric junction. Br J Surg 1998, 85(11):1457-1459.
17. Ruhstaller T, Widmer L, Schuller JC, Roth A, Hess V, Mingrone W, von Moos R, Borner M, Pestalozzi BC, Balmermajno S, et al. Multicenter phase II trial of preoperative induction chemotherapy followed by chemoradiation with docetaxel and cisplatin for locally advanced esophageal carcinoma (SAKK 75/02). Ann Oncol 2009, 20(9):1522-1528. 10.1093/annonc/mdp045, 19465425.
18. Emami B, Lyman J, Brown A, Coia L, Goitein M, Munzenrider JE, Shank B, Solin LJ, Wesson M. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 1991, 21(1):109-122. 10.1016/0360-3016(91)90171-Y, 2032882.
19. Ott K, Bader FG, Lordick F, Feith M, Bartels H, Siewert JR. Surgical factors influence the outcome after Ivor-Lewis esophagectomy with intrathoracic anastomosis for adenocarcinoma of the esophagogastric junction: a consecutive series of 240 patients at an experienced center. Ann Surg Oncol 2009, 16(4):1017-1025. 10.1245/s10434-009-0336-5, 19189186.
20. Becker K, Mueller JD, Schulmacher C, Ott K, Fink U, Busch R, Bottcher K, Siewert JR, Hofler H. Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer 2003, 98(7):1521-1530. 10.1002/cncr.11660, 14508841.
21. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986, 1(8476):307-310.
22. Rizk NP, Tang L, Adusumilli PS, Bains MS, Akhurst TJ, Ilson D, Goodman K, Rusch VW. Predictive value of initial PET-SUVmax in patients with locally advanced esophageal and gastroesophageal junction adenocarcinoma. J Thorac Oncol 2009, 4(7):875-879. 10.1097/JTO.0b013e3181a8cebf, 19487968.
23. Javeri H, Xiao L, Rohren E, Komaki R, Hofstetter W, Lee JH, Maru D, Bhutani MS, Swisher SG, Wang X, et al. Influence of the baseline 18F-fluoro-2-deoxy-D-glucose positron emission tomography results on survival and pathologic response in patients with gastroesophageal cancer undergoing chemoradiation. Cancer 2009, 115(3):624-630. 10.1002/cncr.24056, 19130466.